Back to News and Media

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Publications

This is some text inside of a div block.

September 9, 2025

Media Contacts

Related announcements

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in April Investor Conferences